{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["de Pinieux G"],"funding":["Ligue Contre le Cancer","Fondation ARC pour la Recherche sur le Cancer","Agence Nationale de la Recherche","Institut National Du Cancer","EUROPEAN COMMISSION (EU) EURACAN"],"pagination":["e0246958"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7906477"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(2)"],"pubmed_abstract":["<h4>Background</h4>Since 2010, nationwide networks of reference centers for sarcomas (RREPS/NETSARC/RESOS) collected and prospectively reviewed all cases of sarcomas and connective tumors of intermediate malignancy (TIM) in France.<h4>Methods</h4>The nationwide incidence of sarcoma or TIM (2013-2016) was measured using the 2013 WHO classification and confirmed by a second independent review by expert pathologists. Simple clinical characteristics, yearly variations and correlation of incidence with published clinical trials are presented and analyzed.<h4>Results</h4>Over 150 different histological subtypes are reported from the 25172 patients with sarcomas (n = 18712, 74,3%) or TIM (n = 6460, 25.7%), with n = 5838, n = 6153, n = 6654, and n = 6527 yearly cases from 2013 to 2016. Over these "],"journal":["PloS one"],"pubmed_title":["Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network."],"pmcid":["PMC7906477"],"funding_grant_id":["RESOS","Institut Convergence PLASCAN (17-CONV-0002)","RREPS","Unicancer","LabEx DEvweCAN (ANR-10-LABX-0061),","EC 739521","NETSARC","INTERSARC","Canopee","NETSARC+"],"pubmed_authors":["Mesli N","Penel N","Mescam L","Angot E","Neuville A","Leroux A","Macagno N","Charon-Barra C","de Pinieux G","Moreau A","Jean-Denis M","Coindre JM","Toulmonde M","Gouin F","Ranchere D","Karanian M","Chateau MC","Collin F","Chemin-Airiau C","Rochaix P","Courreges JB","Le Guellec S","Demuret A","Bouvier C","Blay JY","Bazille C","Lae M","Croce S","Robin YM","Terrier P","Stock N","Emile JF","Mishellany F","Le Cesne A","Chabaud S","Birtwisle-Peyrottes I","Weinbreck N","Brouchet A","Ducimetiere F","Le Loarer F","NetSarc/RePPS/ResSos and French Sarcoma Group- Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) networks","Berchoud J","Ghnassia JP","Larousserie F","Aubert S","Chetaille B","Italiano A","Quintin-Rouet I","Delfour C","Fayet Y","Pommepuy I","Ortonne N","Doucet L","Batistella M","Valo I"],"additional_accession":[]},"is_claimable":false,"name":"Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network.","description":"<h4>Background</h4>Since 2010, nationwide networks of reference centers for sarcomas (RREPS/NETSARC/RESOS) collected and prospectively reviewed all cases of sarcomas and connective tumors of intermediate malignancy (TIM) in France.<h4>Methods</h4>The nationwide incidence of sarcoma or TIM (2013-2016) was measured using the 2013 WHO classification and confirmed by a second independent review by expert pathologists. Simple clinical characteristics, yearly variations and correlation of incidence with published clinical trials are presented and analyzed.<h4>Results</h4>Over 150 different histological subtypes are reported from the 25172 patients with sarcomas (n = 18712, 74,3%) or TIM (n = 6460, 25.7%), with n = 5838, n = 6153, n = 6654, and n = 6527 yearly cases from 2013 to 2016. Over these ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2026-05-09T08:54:26.726Z","creation":"2021-03-06T08:16:38Z"},"accession":"S-EPMC7906477","cross_references":{"pubmed":["33630918"],"doi":["10.1371/journal.pone.0246958"]}}